Suppr超能文献

美国犬主的跳蚤/蜱虫防治药物购买情况。

Dog owner flea/tick medication purchases in the USA.

机构信息

Outcomes Research, Animal Health, Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA.

出版信息

Parasit Vectors. 2018 Nov 6;11(1):581. doi: 10.1186/s13071-018-3142-8.

Abstract

BACKGROUND

Veterinary clinic transaction records from the USA were examined to determine dog owner purchase patterns for three prescription ectoparasiticides. In-clinic purchases of formulations of fluralaner (with 12-week duration per dose) were compared with dog owner purchases of afoxolaner and spinosad (both with 4 week duration per dose) in a population of 231,565 dogs over a 12 month period. Prior studies in human and animal medicine have suggested that patients more closely adhere to prescriber dosing recommendations when they receive a longer-duration medication.

RESULTS

Veterinary clinic transaction records were examined for the period June 2014 through March 2017 using records from approximately 650 veterinary clinics. Ectoparasiticide purchase patterns were compared for two products (afoxalaner and spinosad) with monthly dosing and one product (fluralaner) with an extended (12 week) dosing interval. The average dog owner who obtained fluralaner purchased significantly more months of flea/tick protection (5.7 months) over the 12-month study period than the average dog owner that selected either afoxolaner (4.6 months) or spinosad (3.3 months). The proportion of dog owners who obtained only one dose of ectoparasiticide per 12-month period was 42% for fluralaner, 30% for afoxolaner and 37% for spinosad. The proportion of dog owners who obtained 2 doses or less per 12-month period was 67% for fluralaner, 52% for afoxoalaner and 67% for spinosad. Owners that obtained fluralaner were significantly more likely to obtain 7.0-12.0 months of flea and tick protection and significantly less likely to purchase 1.0-6.9 months compared with dog owners who purchased afoxolaner or spinosad.

CONCLUSIONS

Dog owners who obtained a flea and tick medication with a longer duration of action acquired significantly more months of protection in a year than dog owners who obtained shorter duration (1 month) products. Dog owners were better able to adhere to veterinary recommendations on ectoparasites control with a longer-acting flea/tick medication.

摘要

背景

检查了来自美国的兽医诊所交易记录,以确定狗主人购买三种处方驱虫药的模式。在一个为期 12 个月的时期内,对 231,565 只狗的群体进行了比较,比较了在诊所购买氟拉纳(每次剂量持续 12 周)与狗主人购买阿福拉纳和螺旋沙(每次剂量持续 4 周)的情况。在人类和动物医学的先前研究中,当患者接受持续时间更长的药物时,他们更严格地遵循处方剂量建议。

结果

使用大约 650 家兽医诊所的记录,从 2014 年 6 月至 2017 年 3 月期间检查了兽医诊所交易记录。对两种每月剂量的产品(阿福拉纳和螺旋沙)和一种持续(12 周)剂量间隔的产品(氟拉纳)进行了驱虫药购买模式比较。在 12 个月的研究期间,获得氟拉纳的平均狗主人购买了明显更多个月的跳蚤/蜱保护(5.7 个月),而选择阿福拉纳或螺旋沙的平均狗主人分别为 4.6 个月和 3.3 个月。在每个 12 个月期间仅获得一种驱虫药剂量的狗主人的比例为氟拉纳为 42%,阿福拉纳为 30%,螺旋沙为 37%。在每个 12 个月期间获得 2 剂或更少剂量的狗主人的比例为氟拉纳为 67%,阿福拉纳为 52%,螺旋沙为 67%。获得氟拉纳的狗主人明显更有可能获得 7.0-12.0 个月的跳蚤和蜱保护,而购买阿福拉纳或螺旋沙的狗主人则不太可能购买 1.0-6.9 个月。

结论

获得作用时间更长的跳蚤和蜱药物的狗主人在一年内获得的保护月数明显多于获得作用时间更短(1 个月)产品的狗主人。具有长效跳蚤/蜱药物的狗主人能够更好地遵守兽医对寄生虫控制的建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8e1/6218982/4c9eac2f875c/13071_2018_3142_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验